Psychiatric disorders are common and is among the top causes disabilities around the world. On the other hand, although displaying strong genetic correlations, these disorders have been clinically defined as independent categorical entities as they each have some distinguishing clinical symptoms and may involve different treatments. Identifying differential genetic variations between these disorders may shed light on how the disorders differ biologically and help to guide more personalized treatment in the future. Another potential clinical application is differentiating different disorders by genetic markers. For example, a patient who presents with depression may actually be having bipolar disorder (BPD).
Introduction
Psychiatric disorders are common in that more than one-third of people in most countries suffer from at least one kind of disorder in their life 1 . Psychiatric disorders also rank in the top position in terms of total disability-adjusted life years (DALYs) 2 lost. Studies have revealed that various psychiatric disorders show high heritability, likely contributed by a large number of genes, and common variation plays a substantial role 3, 4 . Recent genetic studies based on data from genome-wide association studies (GWAS) have suggested a high genetic correlation between psychiatric disorders 5 .
Moreover, Lee et al. conducted an exploratory analysis of the genetic correlation matrix of eight common psychiatric disorders and observed that they could be arranged to form three groups of inter-related disorders 6 . On the other hand, although displaying strong genetic correlations, these disorders have been clinically defined as independent categorical entities as they each have some distinguishing clinical symptoms and may involve different treatment strategies 7 . Identifying differential genetic variations between these disorders may shed light on how the disorders differ biologically and help to guide more personalized treatment in the future. Another potential clinical application is differentiating different disorders by genetic markers. For example, a patient who presents with depression for the 1 st episode may actually be having bipolar disorder (BD) . It is often difficult to distinguish the two diagnoses but their treatment is different.
Here, we presented a detailed analysis to identify differential genetic markers for psychiatric disorders based on GWAS summary statistics. The analytic framework was successfully validated by simulation firstly, then applied to a variety of psychiatric traits and disorders. We first performed analysis on schizophrenia (SCZ), bipolar disorder (BPD) and major depressive disorder (MDD), which are psychiatric disorders causing major disabilities. Meanwhile, we also performed analysis on six other pairs of genetically related psychiatric disorders. Importantly, we also conducted comprehensive analysis to unravel the genes and pathways involved, and uncovered which cell types and tissues were the most relevant in differentiating the disorders. We also uncovered differences in each studied pair of disorders in terms of their differences in 'comorbid' traits, using LD score regression. Another novel contribution is that by applying a recently developed methodology, we assessed how well we could distinguish two psychiatric disorders (e,g, MDD vs BIP) by the use of polygenic risk scores (PRS). This may be clinically relevant in the future given the lack of biomarkers to aid differential diagnosis of psychiatric disorders.
We take MDD, BPD, and SCZ as examples to illustrate the motivations of our study of differential genetic associations. These disorders are considered to be major health problems because of the high rates of disability and premature mortality caused 8 . These disorders were found to have a close genetic relationship with each other (r g = 0.68 for BPD and SCZ, r g = 0.47 for BPD and MDD, and r g = 0.43 for MDD and SCZ) and could even form a group of inter-related disorders among the eight common psychiatric disorders 5, 6 . Despite this, each of these disorders has its own disorder-specific symptoms and is initially treated by different first-line drugs 9 .
Although being associated with different clinical manifestations, these psychiatric disorders can often be difficult to distinguish, especially in the early course of the disease. BPD and SCZ patients may both psychotic symptoms, while mood symptoms are usually more prominent in BPD. Mood stabilizers such as lithium and valproate however have established efficacy for BPD only. Considering BPD and MDD, BPD patients are often misdiagnosed with MDD initially, especially when presenting in the first episode or if mania/hypomania symptoms are not reported or noticed. This may lead to inaccurate initial treatment. For example, Baldessarini et al. summarized a total of 51 reports of patients diagnosed with MDD and treated with an antidepressant 10 . Their collected data suggested that the overall risk of mood switching from major depression to elevated mood was 8.18% within 2.39 years of treatment. With regard to SCZ and MDD, some patients with depression can present with psychotic symptoms, while social withdrawal and anhedonia that are common in MDD may also be seen in SCZ.
Molecular genetic studies have the potential to distinguish amongst these psychiatric disorders more distinctly since they have a range of moderate to high heritability [11] [12] [13] . Identifying disorder-specific variants and quantifying the contribution of genetic variations may provide crucial clues for clinicians that supplement the purely clinical patterns. Despite this, however, most previous studies have been focused on identifying common shared loci between psychiatric disorders 14 .
However, an effort to explore genetic architecture differences between BPD and SCZ was made by the BPD and SCZ Working Group of the Psychiatric Genomic Consortium 15, 16 . First, they compared 9,252 BPD cases to 7,129 SCZ cases but did not find any SNP reaching genome-wide significance 15 .
Following that, the group established a polygenic risk score (PRS) that was significantly differed between SCZ and BPD patients, indicating that differences between the two disorders have a genetic basis. More recently, they conducted an association analysis with a larger sample size (23, 585 SCZ cases and 15,270 BPD cases) and identified two genome-wide significant SNPs 16 . However, the main concern is that the two studies required individual genotyping data, which necessitated significant manpower and a long period of time that may not suitable for the examination of other disorders. In fact, many of the largest genome-wide association study (GWAS) analyses were conducted by meta-analyses of study-specific results and, therefore, only GWAS summary statistics but not individual genotyping data were typically available for further analyses.
In the current study, we successfully identified a number of differential genetic variants for a total of nine comparisons of psychiatric disorders. Particularly, our results based on GWAS summary data showed almost perfect genetic correlation with those obtained via comparing BPD and SCZ individual genotyping data by the Psychiatric Genomics Consortium (PGC) (r g = 1.054, se = 0.025), indicating a high level of credibility of the ay this study. Importantly, following identification of differential genetic variants, we also conducted functional annotations for these variants in order to elucidate involved tissues, gene sets, pathways, and even specific cell types using bioinformatics tools.
Methods

Study cohorts
We shall first focus on three kinds of psychiatric disorders: SCZ, BPD, MDD. The recent GWAS summary statistics of the three disorders were obtained from a free public database released by the Psychiatric Genomics Consortium (https://www.med.unc.edu/pgc/) and the Complex Trait Genetics (https://ctg.cncr.nl/). In brief, the latest GWAS meta-analysis of SCZ was performed via combining the United Kingdom (UK) CLOZUK sample (11, 260 cases and 24,542 controls) and another independent PGC sample (33,426 cases and 32,541 controls) 17 . After excluding related and overlapping subjects, the largest sample set of SCZ including 40,675 cases and 64,643 controls to date was generated. As for BPD, the largest sample set employed by this study was mainly based on the PGC dataset including 20,129 BPD cases and an independent bipolar specific set of 21,524 controls 16 .
Additionally, a recent GWAS meta-analysis of MDD was carried out based on 29 samples of European ancestry (16,823 cases and 25,632 controls) and six independent European-ancestry cohorts (11, 8635 cases and 319,269 controls), resulting in the largest MDD sample set of 135,458 cases and 344,901 controls 18 . Excluding 23andMe data, the released GWAS summary statistics were generated from a sample set of 59,851 cases and 113,154 controls with a higher SNP-based heritability (7.8%, se = 0.5%). The UK BioBank (UKBB) sub-sample (14260 of 59851 cases) included some cases from self-reporting, while others were defined by clinical assessment or clinical records. Although an updated study reported a larger sample set, the majority of sample (excluding 23andMe) was composed of the broad depression phenotype in the UK Biobank dataset (127552 out of 170756 cases); the sample also showed a lower SNP-based heritability (6.0%, se = 0.3%) 19 . A recent study also showed that genetic studies on depression defined by minimal or 'broad' phenotyping may not be specific to MDD itself 20 . Such studies might identify non-specific non-specific genetic factors linked to other psychiatric conditions; this may defy our purpose of finding differential genetic markers between related psychiatric traits/disorders.
Other studies were All studies included in this work applied otherwise typical inclusion and exclusion criteria for both cases and controls. For further details about the included cohorts, please refer to the original GWAS studies.
Identification of differential genetic markers
Before identifying differential genetic markers, stringent quality controls were applied to the three included GWAS summary statistics. In brief, SNPs with a low imputation quality score (INFO/R 2 < 0.6) and a Hardy-Weinberg equilibrium p-value of below 5 × 10 -6 were excluded from further analysis. In addition, indels and duplicated SNPs were also filtered out. As the summary statistics of the three GWAS datasets were generated from different genotyping platforms and cohorts, the reference allele for signed statistics in a number of SNPs was totally different, indicating that the original statistics were not suitable for direct comparison. We first performed a harmonization step to keep the reference allele for signed statistics between the two comparable GWAS datasets consistent.
Following that, the post-quality-control and harmonized summary statistics were utilized for investigating the differential genetic markers for the nine comparisons of psychiatric disorders using the statistical methods proposed below.
We suggested a simple analytic approach capable of dissecting the genetic differences among differential diagnoses (DDx), relying only on the summary statistics of corresponding diseases.
Specifically, we wished to uncover susceptible genetic variants that can be utilized to differentiate DDx. In essence, with this study, we are "mimicking" a case-control GWAS in which the cases are subjects affected with one differential diagnosis and controls are those affected with the other candidate (differential) diagnosis.
Here, we start by providing the derivation for this method. Suppose and are two binary differential diagnoses. Let be a biallelic SNP. Based on the assumption of logistic regression for the involved binary traits, they can be represented as follows:
Where = ( = 1) and = ( = 1) denote the disease prevalence of corresponding traits in the collected dataset. ( = 1,2,3) indicates the error term for corresponding regression model.
Based on the definition of odds ratio, for traits and , we have:
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Suppose the controls selected for two differential diseases come from the same population. In this regard, Pr( = 0| = + 1, ) and Pr( = 0| = , ) are approximately the same as those for trait . Thus, the odds ratio for two differential diseases can be given as:
( 1 2
where = {0,1} denotes the value of interested genetic variants. In other words, the effect size of differential association (i.e. trait 1 as case and trait 2 as control) can be derived from the difference of effect sizes of the respective traits. Following the basic properties of variance, the variance of can be expressed as:
( , ) depends on the actual overlap between the samples and can be derived from multiplying the SEs of the two coefficients with the intercept from cross-trait LD score regression (see
Functional annotations of identified differential genetic variants
The differential genetic variants identified by this study were further explored for their potential biological function using the FUMA program (https://fuma.ctglab.nl/) 22 . All the candidate SNPs in defined associated genomic risk loci that are in LD (r 2 ≥ 0.6) with the corresponding independent significant SNPs were selected for functional annotations, which were obtained via matching their chromosomes, physical positions, and reference and alternative alleles to databases that have known functional annotations, mainly including combined annotation-dependent depletion (CADD) scores 23 , chromatin states 24, 25 , ANNOVAR categories 26 and RegulomeDB scores 27 . The CADD score is a marker of the deleteriousness of SNP's effect on protein structure/function, with a higher score indicating a higher level of deleteriousness. The chromatin state indicates the accessibility of genomic regions with 15 categorical states. A hidden Markov model was adapted to predict the state according to five types of chromatin marks for 127 epigenomes derived from the Roadmap Epigenomics Project 25 . The ANNOVAR categories mainly locate SNP's genetic position and its potential function on the corresponding gene. The RegulomeDB scores predict the likelihood that an SNP has a regulatory role ranging from 1a to 7, with a lower score referring to an increased likelihood.
Gene mapping
The differential genetic variants were also explored to identify their mapped genes in FUMA using three different strategies including positioning, expression quantitative trait locus (eQTL), and chromatin interaction (CI) mapping. In brief, the positional mapping method maps variants to genes based on their physical position, while the eQTL mapping strategy maps SNPs to genes with which they have a significant eQTL association. We selected all tissue types and established a false discovery rate (FDR) of 0.05 to get the significant SNP-gene pairs. The third strategy is the CI mapping method, which maps SNPs to genes bases on a three-dimensional (3D) DNA-DNA interaction of the SNP region with a gene region. We included all built-in chromatin interaction data for analysis, which contain Hi-C datasets of 21 tissues and cell types from GSE87112. To increase the likelihood of the identified regions having a plausible biological function, we only mapped SNPs that were overlapped with enhancers and promoters of the Roadmap 111 epigenomes. An FDR threshold of 1 × 10 −5 was set to define the significant interaction of the SNP region with a gene region.
Genome-wide gene-based association study (GWGAS) and functional annotations
The P-values of differential genetic markers from SNP-based GWAS were utilized for GWGAS analysis in the MAGMA program 28 . Briefly, the mapped protein-coding genes by the input SNPs were treated as the basis for GWGAS. The definition of the mapped genes is that one gene should contain at least one GWAS SNP. The FDR method was employed to adjust for multiple testing and genes with an adjusted P-value below 0.05 were considered to have statistical significance.
The biological functions of GWGAS significant genes were further investigated via tissue-specific and cell-type-specific expression enrichment analysis using MAGMA and Linkage Disequilibrium SCore regression (LDSC) programs 29 . In tissue-specific enrichment analysis, the gene expression values from 53 whole-body general tissues obtained from the GTEx project were employed. Since most brain regions were found to be enriched in the tissue-specific enrichment analysis step, we mainly focused on the brain region in the two-step cell-type-specific enrichment analyses. First, we conducted an enrichment analysis in 13 brain regions using data from the GTEx project in the LDSC program. The gene expression data from only the brain samples extracted to differentiate among brain regions, i.e., t-statistics, were computed within the brain-only dataset. Following that, all available single-cell expression datasets from human brain regions in FUMA were included for enrichment analysis to explore the contributing neurons within one specific brain region. Conditional analyses were carried out using MAGMA to identify the independent contributing neurons that drove the observed association. In this analysis, each pair of marginally associated cell types (e.g., cell types 'a'
and 'b') within one single-cell expression dataset were compared to determine one independent significant cell type. For example, cell type 'a' was retained if the association of cell type 'b' was completely dependent on the association of 'a' (conditional state: 'drop' against 'main') or the association of 'b' is mostly explained by 'a' but there are parts of the association dependent on both cell types (conditional state: 'joint-drop' against 'partial-joint').
We also conducted pathway and gene-set enrichment analyses to explore whether these significantly associated genes were enriched through biological predefined pathways or gene sets in the ConsensusPathDB database (CPDB, human) (http://consensuspathdb.org/) 30 . The predefined pathways were defined by pathway databases, including KEGG, Reactome, Wikipathways, and other pathways. Regarding the predefined gene sets, Gene Ontology (GO) level 5 categories involved in biological processess, molecular functioning, and cellular components were included for enrichment analyses. Pathways or gene sets with a q-value below 0.05 were considered as significantly enriched signals.
Genetic correlation calculation for related traits
Genetic correlations (r g ) between the identified differential genetic variants and 42 potentially related phenotypes were calculated using the LDSC program (http://ldsc.broadinstitute.org/centers/) 31 .
The rationale of this analysis is that when we consider two disorders as different, it is important to see whether they are associated with different comorbid disorders or traits. This distinction is important to help us understand the different prognosis or aetiology of different disorders. For example, SCZ is generally associated with more prominent cognitive deficits than BPD, which may affect patient's social and occupational functioning. The analysis of genetic correlation will help highlight differences like this.
The GWAS summary statistics of 42 phenotypes were obtained from the LD Hub centres and grouped into nine categories of traits including neurological diseases, personality traits, sleeping, cognitive, education, brain volume, psychiatric diseases, cardiometabolic traits, and aging. Adjusted P-values by FDR below 0.05 were considered statistically significant; those with FDR<0.2 were considered suggestive associations.
Ability of polygenic risk scores to differentiate disorders
The obtained GWAS summary statistics were utilized to calculate an area under the curve (AUC)
indicating the degree to which polygenic scores from the identified genetic variants can differentiate two compared psychiatric disorders, such as BPD and MDD. An empirical Bayes approach has been proposed to recover the underlying effect sizes and could be used to forecast predictive ability of polygenic scores, based on summary statistics alone 32 . Eighteen subsets of genetic variants based on a series of P-value thresholds (1 × 10 −5 , 1 × 10 −4 , 5 × 10 −4 , 1 × 10 −3 , 5 × 10 −3 , 0.01, 0.03, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1) were used to construct the PRS.
Simulation
To verify the feasibility and efficacy of our proposed method in uncovering genetic differences among closely related disorders, we simulated different scenarios of genotype-phenotype data with 300 genotypes (i.e., N snp = 300; coded as 0, 1 and 2) and 2 binary differential diseases (coded as 0 and 1, where 1 indicates the status of having disorder). Since the proposed framework is basically a SNP-based analysis, the number of simulated genotypes shall not affect the validity of the simulated scenarios. The allele frequency for each simulated SNP was randomly generated from a uniform distribution with a value range of [0.05, 0.95]. The number of subjects with each disorder (i.e., ncases)
was set to [10000, 20000, 50000, 100000] with a disease prevalence (K) of 10%. Here, ncases denotes the expected number of cases in the whole simulated population cohort. Given the disease prevalence, we could know the sample size of the whole simulated population cohort (ntotal), i.e., = .
The total SNP-based heritability (ℎ ) for each trait was set at 0.2 to 0.4, distributed among all SNPs.
More specifically, we simulated standard normal variables zi ~ N(0,1), and set mean effect size µ = . The actual effect size for SNPi was set at βi =µ zi . The total liability y equals the sum of effects from each SNP plus a residual (e), i.e. = ∑ + ; the total variance of y was set to one.
Following the liability threshold model, subjects with total liability exceeding a certain threshold [= Φ ( ), where K is the disease prevalence] are regarded as having the trait or disease. The non-shared genetic covariance between the two traits was set to 0.1.
From the simulated population cohort, we simulated two case-control studies with trait A and B
as the outcome respectively. Suppose the number of cases for trait A and B in the simulated population cohorts are respectively and , and = ( , ). For trait A, we picked cases and 2 − controls from the population. As for trait B, we picked cases and 2 − controls from the population. For comparison, we also simulated a "real" GWAS comparing the two disorders. All cases who are identified as having trait A but not trait B were selected as cases ( _ );
all cases who are identified as having trait B but not trait A are selected as controls ( _ ). To demonstrate the validity of our current method, we also simulated case-control samples with different overlap rate (P) for both traits. Here, P indicated the ratio of overlapped samples and all picked samples for each case-control study, i.e., = .
2 ⁄ . To adjust the overlap rate, we need to adjust the number of common controls for both traits. Since our proposed method is based on case-control studies, K shall not affect the validity of simulated scenarios, as it only affects the number of overall controls in the simulated population cohort.
Results
Please note that all supplementary tables are available at https://drive.google.com/open?id=1qrpDV6GhobffSwOtRsmAkPY_CihIpHuA
Simulation results
Table 1 demonstrates our simulation results (For more details, please refer to Supplementary Materials no. 0 (SM. 0)). The correlations between the estimated and actual coefficients for the GWAS analysis are very high with different sample sizes of cases. As shown in Table 1 , the correlation and RMSE improved with increased sample size and overlap rate. Since the sample sizes of cases for current GWAS summary data are usually larger than 10,000, our proposed method are sufficiently good to approximate the coefficients from GWAS summary data of corresponding traits.
Clearly, the power of our proposed method increased with larger case sizes and heritability explained by SNPs. In addition, there was no observed inflated type I error when simulated SNPs with p<=0.05 were considered significant.
SCZ against MDD
Identification of differential genetic markers and functional annotations
The SCZ and MDD GWAS summary statistics generated from 105,318 subjects and 480,359 subjects, respectively, were compared to find out differential genetic variants. A flowchart showing the study methodology is presented in Fig. 1 . After conducting stringent quality control and a harmonization step as stated in the 'Methods' part, 7,530,283 variants remained for follow-up comparison. In the comparison of the two summary statistics, 2,312 variants located in 37 genomic risk loci were elucidated and reached genome-wide significance (P < 5 × 10 −8 ) [ Figure 2A , Table 3 , Supplementary materials no. 1 (SM.1), and Supplementary Table 1 (ST.1)]. Based on each genomic locus of the 37 genomic loci, a total of 83 SNPs were identified to be the independent genome-wide significant variants in an approximate LD (r 2 ≥ 0.6). In these loci, 6,688 candidate SNPs were indexed by the corresponding independent significant SNPs (SM.1 and ST.2). Although most of the candidate variants were located in intergenic and intronic regions (81% of all candidate variants) ( Figure 2C . These findings indicated that biological functions involving differential genetic variants between SCZ and MDD included functional categories that were common across species, those that directly influence the function of coding proteins, and those that indirectly affect function by regulatory mechanisms.
Gene mapping, GWGAS, and functional annotations
We employed three gene-mapping strategies to link the associated SNPs to genes. The positional mapping method mapped associated variants to 206 genes by physical position, eQTL mapping strategy aligned the associated SNPs to 228 genes based on cis-eQTLs effect, and the 3D CI mapping method mapped associated variants to 388 genes ( Figure 3B , SM.1, and ST.5). The three mapping strategies generated a set of 524 unique genes, 94 of which were implicated by all three strategies. In addition to the three gene mapping strategies, we also conducted GWGAS to link the associated GWAS SNPs to genes. Being different from the FUMA mapping method aligning individually significant SNPs to genes, the GWGAS analysis considered the accumulating association of all SNPs in one gene. This analysis identified 953 significantly associated genes [ Figure 3A , SM.1, and ST.6; P (FDR) < 0.05]. Taken together, a total of 64 genes were implicated by all four strategies ( Figure 3B ).
Among the 64 candidate genes, the CACNA1C gene was predicted to have a very high probability of loss of function mutation intolerance (pLI score = 0.999998). Furthermore, we found that there were 89 unique genome-wide significant SNPs within this gene, although all of them were located in the intronic region (SM.1 and ST.2). The effect size for each of the 89 variants was relatively small, but the accumulating effect of them significantly increased the probability of the loss of function in this gene.
During the tissue-specific expression enrichment analysis for 53 general tissue types, the GWGAS significant genes were enriched for all 14 brain regions but not for any of the other regions (SM.1 and ST.7), which in turn indicated that the identified associated gene by GWGAS had a high level of credibility. To further reveal the independent contributing brain region, we performed a cell-typespecific enrichment analysis based on the RNA-seq data from only the brain samples and observed that the cortex region, the anterior cingulate cortex (BA24), and the frontal cortex (BA9) were the independently associated signals that may be accounting for the association of the other brain regions ( Figure 3C Conditional analyses were performed for those datasets with more than one nominally significant cell type. Neurons in the cortex region, GABAergic neurons in the midbrain region, and pyramidal neurons in the hippocampus region were determined as independent contributing neurons ( Figure 3E , SM.1, and ST.10). Of note, the inconsistent association results for the hippocampus region between the cell-type-specific within-brain enrichment analysis [P (FDR) = 9.48 × 10 −1 ] and neuron-specific enrichment analysis [P (FDR) < 3.48 × 10 −2 ] may be induced in two ways: (1) different processing methods for gene expression value in different studies and (2) heterogeneity between different neurons within the same brain region 33 .
During gene-set enrichment analysis, we observed that the 953 significantly associated genes were 
Genetic correlation with related traits
Since SCZ and MDD have been reported to be individually associated with various psychiatric traits or volume of brain regions 5,34-37 , we conducted genetic correlation analyses between the identified differential genetic variants and 42 potentially related traits (SM.1 and ST.13). In the present study, SCZ was defined as the case and MDD was the pseudo-control. Note that a positive genetic correlation indicates that the 'case' disorder is more positively associated with the studied trait genetically than the '(pseudo)control' disorder, and vice versa.
We observed a strong positive correlation with BPD was observed [r g = 0.710; P (FDR) = 1.12e-63]
as SCZ and BPD were two highly correlated disorders 16 . Additionally, we also identified positive genetic correlations of differential genetic variants with another two neurological traits, i.e., anorexia 
AUC calculation
The empirical Bayes approaches proposed by our team before were employed to construct a PRS system to investigate how two psychiatric disorders were differentiated by the identified genetic variants 32 . Eighteen subsets of genetic variants in successional P-value thresholds were used to construct different PRSs weighted by their effect sizes. In this analysis, the P-value threshold of 0.005 was determined to have the largest differentiating ability [AUC = 0.738; Figure 4 , SM.1, and ST.14].
Accumulating evidence suggested that the prevalence rates of SCZ and MDD were about 0.5% and 13.0%, respectively 38, 39 .
In the analysis, we assume each subject is either having one of the disorders (e.g. in this case we assume the different diagnosis (ddx) has been narrowed down to either SCZ or MDD). The prior probabilities (without genetic information) of being affected with either disorder are based on lifetime prevalence of the disease. For example, based on the prevalence above, we assume that a person has ~13/0.5 ~26 times of being affected by MDD than SCZ. Our analytic framework actually allows more flexible setting of these prior probabilities, although we made simpler assumptions here. We expect that with the addition of polygenic scores, one would be able to differentiate the disorders more accurately. AUC under the ROC curve is one way to quantify the discriminating ability; we also With an increase in risk score, the risk of SCZ became higher, while the risk of MDD tended to be lower. Subjects with the upper 5% of the risk score had a substantially decreased relative risk of 8.5
when comparing the risks of SCZ vs MDD. Note that at the start we assume ~26 times higher risks of MDD than SCZ based on overall lifetime risks; a reduction of this ratio to 8.5 times is a relatively large change. Together, the analysis may provide additional important data to clinicians regarding the risk of the two disorders in addition to the population prevalence rates of the two disorders.
BPD against MDD
Identification of differential genetic markers and functional annotations
The BPD and MDD GWAS summary statistics derived from 41,653 subjects and 480,359 subjects respectively were compared to identify differential genetic variants. Following stringent quality control and a harmonization step, 8,130,000 variants remained available for the following comparison. In the heritability enrichment analyses for differential genetic variants, we observed that the and super-enhancer site [P (nominal) = 6.98 × 10 −5 ] were identified as enrichment factors for the heritability of SNPs, indicating that they indirectly affect the function of protein by regulatory mechanisms also involved in differential genetic markers between BPD and MDD.
Gene mapping, GWGAS, and functional annotations
In the three gene-mapping strategies, the positional mapping method was used to map associated variants to 18 genes, the eQTL mapping strategy aligned associated SNPs to 90 genes, and the CI mapping method mapped associated variants to 66 genes [ Figure The three mapping strategies generated a set of 92 unique genes including four that were implicated by all these strategies. Further, the GWGAS analysis identified 174 significantly associated genes . At this point, the STK4 gene had been already implicated by functional annotations involving in differential genetic variants. The CTTNBP2 gene was predominantly expressed in the brain and regulated dendritic spinogenesis, which is the reason for why this gene is associated with autistic spectrum disorder (ASD) 40 
Genetic correlation with related traits
Genetic correlation analyses between the identified differential genetic variants and 42 potentially related traits were performed to investigate whether the differential variants between BPD and MDD were correlated wth these traits at the genetic level (SM.2 and ST.12). In this comparison, BPD was defined as the case and MDD was the pseudo-control. We found a strong positive genetic correlation with one previous BPD GWAS dataset [ which was also implied by the mapped gene CILP2.
AUC calculation
A polygenic risk score system was constructed to tell BPD from MDD and revealed that the P-value threshold of 0.01 had the highest differentiating ability (AUC = 0.622; SM.2 and ST.13). The prevalence rates of BPD and MDD were approximately 2.4% and 13%, respectively 38, 45 . Based on the constructed PRS system, subjects with the lower 5% of risk score have a lower risk of BPD but a higher risk of MDD (relative risk of MDD/BPD is 12.51) (SM.2 and ST.13). With an increase in risk score, the risk of BPD became higher, while the risk of MDD tended to be lower. Subjects with the upper 5% of risk score presented a substantially decreased relative risk (MDD/BPD) of 2.83. Together, the calculated relative risk offers additional information to clinicians for giving a diagnosis of BPD or MDD and prescribing initial drugs for patients.
SCZ against BPD
Identification of differential genetic markers and functional annotations
The SCZ and BPD GWAS summary statistics derived from 105,318 subjects and 41,653 subjects, respectively, were compared to elucidate differential genetic markers. Through the conduct of stringent quality control and a harmonization step, 7,676,685 variants were selected for further computation. After comparing the two invoking summary statistics datasets, 45 variants located in three genomic risk loci were identified and passed the genome-wide In the heritability enrichment analyses for differential genetic variants, we observed that the mechanisms are involved in differential genetic markers between SCZ and BPD.
Gene mapping, GWGAS, and functional annotations
In the three gene-mapping strategies, the positioning mapping method mapped associated variants to 36 genes, the eQTL mapping strategy aligned associated SNPs to 35 genes, and the CI mapping method mapped associated variants to 67 genes [ Figure (Venn diagram) , SM.3, and ST.5]. The three mapping strategies generated a set of 97 unique genes, including 12 indicated by all the strategies.
Consistent with the functional annotations of all candidate variants, seven of 12 mapped genes belong to the zinc finger protein-encoding gene family (ZSCAN16, ZKSCAN8, ZSCAN9, ZKSCAN4, ZSCAN12, TRIM27, and ZNF311). Besides, the HIST1H3J gene was predicted to have a high probability of the loss of function mutation intolerance (pLI = 0.696). Moreover, this gene was reported to be associated with neuroticism in the largest genome-wide association study to date 46 but not with SCZ or BPD before. The GABBR1 gene had the highest probability (pLI = 1.000) and encoded a receptor for gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the mammalian central nervous system. 
Genetic correlation with related traits
Genetic correlation analyses of the differential genetic variants with 42 types of related traits were carried out. In this comparison, SCZ was defined as the case and BPD was defined as the pseudo-control. A strong positive genetic correlation with one previous SCZ GWAS dataset [SM.3 and ST.12; r g = 0.524; P (FDR) = 1.31 × 10 −76 ] and a negative correlation with one previous BPD GWAS dataset [r g = −0.457; P (FDR) = 6.15 × 10 −21 ] were observed, which confirmed the reliability of the methodology proposed by this study. In addition, the analyses also implied a significant negative correlation with four education traits [r g < −0.191; P (FDR) < 1.03 × 10 −3 ], which indicated that subjects with BPD were likely to have a higher level of education than those with SCZ. Moreover, subjects with BPD may also have a higher level of intelligence [r g = −0.255; P (FDR) = 1.00 × 10 −6 ]
and subjective well-being [r g = −0.162; P (FDR) = 1.03 × 10 −2 ]. Besides, a significant negative correlation with chronotype was observed [r g = −0.134; P (FDR) = 1.03 × 10 −2 ], indicating subjects with BPD may be more likely sensitive to the change in chronotype.
AUC calculation
A polygenic risk score system was constructed to distinguish the two disorders and observed that the P-value threshold of 0.005 had the highest ability of differentiation [AUC = 0.627; SM.3 and ST.13]. Accumulating evidence indicated that the prevalence rates of SCZ and BPD were approximately 0.5% and 2.4%, respectively 39, 45 . Based on the constructed PRS system, subjects with the lower 5% of risk score had a lower risk of SCZ but a higher risk of BPD (relative risk of BPD/SCZ is 11.5) (SM.3 and ST.13). With the increase in risk score, the risk of SCZ became higher while the risk of BPD tended to be lower. Subjects with the upper 5% of risk score had a substantially decreased relative risk (BPD/SCZ) of 2.44.
Six other comparisons
As stated before, the proposed methodology only requires GWAS summary statistics and can be easily applied to other disorders. In the present study, we also aimed to identify differential genetic variants of the other six comparisons of psychiatric disorders, including ASD against ADHD, ASD against MDD, ADHD against MDD, ED against MDD, obsessive-compulsive disorder (OCD) against comparisons, please refer to SM.4 through SM.9. GWAS summary statistics of ED released in 2017 47 rather than those in 2019 48 were employed by the study as it offered a higher heritability (24.1% vs. 17 .8%); the same was true for PTSD (2.22% vs. 1.25%) 49, 50 .
We identified plenty of significantly associated differential genetic variants for the former four comparisons (404, 64, 161, and 94 respectively; Table 1 , SM.4-7, and ST.1). For the comparison of ASD against ADHD, a total of eight genes were mapped by all of the four mapping strategies (SM.4, ST.5, and ST6). Furthermore, most of these genes were also implicated by the candidate SNPs in the seven genomic risk loci, indicating that the function of these genes may be strongly influenced by the With regard to the latter two comparisons, we observed nine and 12 genomic risk loci for PTSD against MDD and OCD against MDD, respectively (Table 1) , although only a number of variants passing the genome-wide suggestive threshold were identified (SM.8, SM.9, and ST.1). When comparing OCD and MDD summary statistics, we identified the only significantly associated gene KIT by the GWGAS method [P (nominal) = 3.08 × 10 −8 and P (FDR) = 5.76 × 10 −4 ] (SM.9 and ST. 5).
The functional annotations of candidate SNPs in the 12 genomic risk loci showed the strongest deleterious variant rs3756197 (CADD score = 21.2, MAF = 0.3728; SM.9 and ST. 2), which may induce the dysfunction of the gene.
Discussion
The present study applied a simple yet useful analytic framework to identify differential genetic markers for a board range of psychiatric disorders, and we conducted detailed secondary analysis to identify the genes, pathways and cell-types/tissues implicated. The three disorders showed some overlapping symptoms clinically and were found to have close genetic correlations 5 ; it is therefore difficult to distinguish between them, especially during the early course of disease. Identifying disorder-specific variants and quantifying the contribution of genetic variations may play a crucial role in understanding the disorder-specific mechanism. The BPD and SCZ Working Group of the PGC tried to find the differential genetic variants between BPD and SCZ in 2014 15 . Although unable to identify any genome-wide significant SNPs, they suggested that differences between the two disorders have a genetic basis. However, the performed association studies needed individual genotyping data, which may not be available for the other disorders. In contrast, the framework presented by the current study only required GWAS summary statistics and could be easily applied to the other psychiatric and nonpsychiatric disorders. Employing appropriate GWAS summary statistics, we successfully found out 37 genomic risk loci differentiating SCZ and MDD, four loci differentiating BPD and MDD, and three loci differentiating SCZ and BPD.
Regarding the comparison between SCZ and BPD, the three genomic risk loci containing 45 genome-wide significant SNPs were located in chromosomes 6, 7, and 12, respectively. The BPD and SCZ Working Group of the PGC conducted an association study based on individual genotyping data and identified two different genome-wide significant SNPs in 2018 16 . The difference may be mainly induced by the employed datasets. We employed later and larger GWAS summary statistics of SCZ able to provide a bigger power 17 , while the Working Group of the PGC adopted a relatively smaller individual genotyping dataset of SCZ. Based on the three identified genomic loci in this study, the functional annotations for the significant SNPs and those candidate variants implied that the olfactory receptor family and the zinc finger protein-encoding gene family may be involved in the differentiating mechanism. The four different gene mapping strategies confirmed the involvement of the zinc finger protein-encoding gene family because the five genes mapped by all four methods belonged to this gene family. Accumulating evidence indicated that some of the family members such as ZNF804A are involved in the pathology of brain development and the aetiology of psychiatric disorders, especially for SCZ and BPD [51] [52] [53] . Besides, we also observed the involvement of other genes in the differentiating mechanism; for example, the GABBR1 gene, encoding a receptor for GABA, had the highest probability of loss of function mutation intolerance.
In addition, to compare SCZ and BPD, the present study firstly successfully identified a number of differential genetic markers between BPD and MDD as well as SCZ and MDD. BPD and MDD are two closely related disorders as both of them involve an episode of major depression. The main clinical difference is that BPD includes an additional episode of hypomania or mania. Investigating the differential genetic markers between them may enhance the knowledge of understanding the switching pattern and reduce the risk of mood switching when undergoing an antidepressant treatment in MDD 10 . The current study identified 42 genome-wide significant variants located in four genomic risk loci. Functional annotations of these significant variants and those candidate variants indexed in LD suggested that the dysfunction of the SUGP1 gene may be involved in the differentiating mechanism. The encoded SUGP1 protein was identified to be an important regulator of cholesterol metabolism 54 . Moreover, the CILP2 gene mapped by all four strategies was found to significantly affect both the levels of low-density lipoprotein cholesterol and triglycerides as well as the risk of CAD 41 . Besides, the genetic correlation analysis identified a strong negative correlation between BPD and CAD. Taken together, the differential genetic variants between BPD and MDD may have a strong association with the cholesterol metabolism and the risk of CAD.
For MDD and SCZ, they are genetically correlated but also have distinct clinical presentations with different treatments. Identifying differential genetic markers could reveal the genetic basis for the clinical difference. The present study firstly identified a total of 2,312 genome-wide significant variants, which formed 37 genomic risk loci. Functional annotations of the 6,688 candidate SNPs in these loci observed the strongest signal rs13107325, which causes the worst deleteriousness to the corresponding gene SLC39A8. This SNP is a functional missense variant at the metal cations transporter and is one of the most pleiotropic variants displaying a genome-wide significant association with several traits including Crohn's disease, high-density lipoprotein cholesterol, and body mass index, especially for SCZ 55 . Recently, this SNP was reported to show the strongest signal (CADD score = 34; P = 2.23 × 10 −21 ) out of 146 exonic nonsynonymous variants, altering the risk of intelligence 56 , which was further confirmed by the strong genetic correlation with intelligence in this study [r g = −0.173; P (FDR) = 2.52e-07]. Additionally, the four mapping strategies identified a total of 64 genes involved in the differential genetic basis. Among them, the CACNA1C gene, encoding calcium voltage-gated channel subunit alpha1C, was functionally implicated in a board spectrum of psychiatric disorders and sleep problems 57 . Moreover, the SNAP91 gene, encoding synaptosome associated protein 91, is a direct synaptic component in the presynaptic terminal of neurons involved in neurotransmission and neurodevelopment. This gene was found to be one cis-expression quantity trait locus with SCZ GWAS loci 58 .
The cell-type-specific enrichment analysis implied that the frontal cortex (BA9) and anterior cingulate cortex (BA24) were significantly enriched by the identified differential genetic variants between SCZ and BPD, the cortex and frontal cortex (BA9) by the differential variants between BPD and MDD, and all the three brain regions by the differential variants between SCZ and MDD.
Brodmann area 9 is part of the frontal cortex, the dysfunction of which underlies many cognitive and behavioural disturbances that are associated with psychiatric disorders, such as SCZ, MDD, ADHD, and ASD 59, 60 . Moreover, one previous meta-analysis of magnetic resonance imaging studies in BPD implied a decreased volume in the left rostral anterior cingulate cortex 61 . The present study was the first time to imply the involvement of the three brain regions in the differential genetic basis. Besides, the neuron-specific enrichment analysis found out the contributing neurons in the cortex and prefrontal cortex for the comparison of SCZ and MDD. We observed that the hybrid and neurons in the cortex region and GABAergic neurons in the prefrontal cortex were the contributing neurons through analysing 166 different cell types.
Gene-set and pathway enrichment analyses suggested that the inositol metabolism pathway may be involved in the differential genetic basis between SCZ and BPD as well as between BPD and MDD.
This signalling system is a postreceptor second messenger signalling system that exists in many cells and a change in the central nervous system inositol level may cause the dysfunction of the system, which may induce the occurrence of psychiatric disorders such as bipolar disorder, depression, and anxiety disorder 42, 44, 62, 63 . With regard to the comparison between SCZ and MDD, pathways related to the regulation of nervous system development, neuron differentiation, neuron projection development, and postsynaptic and presynaptic nicotinic acetylcholine receptors were significantly enriched by the differential genetic variants.
Genetic correlation analyses for the differential genetic variants between SCZ and BPD indicated that subjects with BPD are likely to have higher levels of education, intelligence, and subjective well-being relative to those with SCZ. A similar circumstance was also observed in the comparison between BPD and MDD, where BPD had a significant positive correlation with childhood intelligence quotient and a higher level of education. Previous evidence has indicated that BPD subjects who experience hypomania present increased creativity and probands of people with BPD are more likely to be professionally successful 64, 65 . Regarding the comparison between SCZ and MDD, it was worthwhile to mention that SCZ had a strong negative correlation with hippocampal volume, which was corroborated by the strong association with the hippocampus region in the cell-type enrichment analysis. Both SCZ and MDD patients were found to have smaller volumes of several brain regions including the hippocampus 37, 66 . However, a previous study showed that there was a larger reduction in hippocampal volumes for SCZ patients compared to those with MDD 67 . Our genetic correlation analysis supports this finding.
The polygenic risk system constructed by the empirical Bayes approach based on GWAS summary statistics implied that P-values at relatively low levels of 0.005, 0.005 and 0.01 are optimal thresholds for the three comparisons respectively. The differential genetic variants between SCZ and MDD had the largest differentiating ability (AUC = 0.738). Furthermore, the relative risk analysis derived from the constructed PRS may provide additional risk score profiling capabilities to clinicians, if our findings are replicated in future studies. Differential diagnosis is often difficult in psychiatry due to the lack of objective biomarkers. Especially if the subject presents with some intermediate symptoms,
one may need to rely on how common each disorder is to help make decisions. The constructed risk score profiling approach could provide a more comprehensive and biologically-informed approach to estimate the relative risk of one subject suffering from either of the two disorders. For instance, even if one disorder A is more common than the other (B), if a patient is at the high end of PRS of the less common disorder, he/she may still be a relatively high risk for B.
Although it successfully identified differential genetic markers for the three comparisons, the current study has several limitations. In summary, the presented framework successfully identified several differential genomic risk loci for the three main comparisons and the other six comparisons outlined. Moreover, functional annotations of differential genetic variants not only confirmed some previous observations but also revealed many novel genes, pathways, tissues, and even specific cell types involving in the aetiology of the differentiation mechanism. The relative risk of the two target disorders from a polygenic score analysis may provide additional important information to clinicians to facilitate the diagnosis and personalized treatment of psychiatric patients.
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